(Q53968585)

23 May 2018

title

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. (English)

1 reference

23 May 2018

1 reference

Neuvonen PJ

1

1 reference

23 May 2018

Kantola T

series ordinal

2

1 reference

23 May 2018

Kivistö KT

series ordinal

3

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 March 1998

1 reference

23 May 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

23 May 2018

volume

63

1 reference

23 May 2018

issue

3

1 reference

23 May 2018

page(s)

332-341

1 reference

23 May 2018

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Drug-interaction-induced rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

CYP3A gene expression in human gut epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Metabolism of pravastatin sodium in isolated rat hepatocytes. I. Glutathione conjugate formation reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

10.1016/S0009-9236(98)90165-5

7 January 2021

Identifiers

DOI

1 reference

23 May 2018

release_qsytufbfkbejphobywdsurioxy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qsytufbfkbejphobywdsurioxy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

23 May 2018